NCI names 11 winners of its Cancer Clinical Investigator Team Leadership Awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI recognized 11 investigators nationwide with its Cancer Clinical Investigator Team Leadership Awards.

The awards support clinical investigators at NCI-designated cancer centers who participate in NCI-funded clinical trials. Established in 2009, the awards are intended to help retain investigators in academic clinical research careers. The award provides partial salary support for 2 years for the recipient to engage in activities and efforts related to the award.

The 2015 recipients are:

  • Leora Horn, of Vanderbilt-Ingram Cancer Center
  • David Hyman, of Memorial Sloan-Kettering Cancer Center
  • Matthew Katz, of MD Anderson Cancer Center
  • Edward Kim, of UC Davis Comprehensive Cancer Center
  • Frederick Lansigan, of Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
  • Charles Leath III, of University of Alabama at Birmingham Comprehensive Cancer Center
  • Elizabeth Plimack, of Fox Chase Cancer Center
  • Andrew Poklepovic, of Massey Cancer Center at Virginia Commonwealth University
  • Yvonne Saenger, of Columbia University’s Herbert Irving Comprehensive Cancer Center
  • Emma Scott, of Oregon Health & Science University Knight Cancer Institute
  • Liza Villaruz, of the University of Pittsburgh Cancer Institute

For details of the 2016 program announcement, open through Dec. 4, visit the NCI website.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login